Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more
Shenzhen Lifotronic Technology Co (688389) - Total Liabilities
Latest total liabilities as of September 2025: CN¥549.45 Million CNY
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has total liabilities worth CN¥549.45 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Lifotronic Technology Co - Total Liabilities Trend (2016–2024)
This chart illustrates how Shenzhen Lifotronic Technology Co's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shenzhen Lifotronic Technology Co Competitors by Total Liabilities
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Veradigm Inc.
NASDAQ:MDRX
|
USA | $513.64 Million |
|
GSR III Acquisition Corp. Unit
NASDAQ:GSRTU
|
USA | $10.07 Million |
|
Hangzhou Star Shuaier Electric Appliance Co Ltd
SHE:002860
|
China | CN¥1.33 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥1.10 Billion |
|
Yuhuan CNC Machine Tool Co Ltd
SHE:002903
|
China | CN¥396.62 Million |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
USA | $27.31 Million |
|
Titan International Inc
NYSE:TWI
|
USA | $1.15 Billion |
|
JSL Construction & Development Co Ltd
TW:2540
|
Taiwan | NT$40.63 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Shenzhen Lifotronic Technology Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Lifotronic Technology Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Lifotronic Technology Co (2016–2024)
The table below shows the annual total liabilities of Shenzhen Lifotronic Technology Co from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥845.13 Million | +58.34% |
| 2023-12-31 | CN¥533.76 Million | +41.57% |
| 2022-12-31 | CN¥377.02 Million | +74.14% |
| 2021-12-31 | CN¥216.50 Million | +48.31% |
| 2020-12-31 | CN¥145.98 Million | +12.91% |
| 2019-12-31 | CN¥129.29 Million | -9.92% |
| 2018-12-31 | CN¥143.53 Million | +16.56% |
| 2017-12-31 | CN¥123.15 Million | -2.80% |
| 2016-12-31 | CN¥126.69 Million | -- |